3-Methoxy-catalposide inhibits inflammatory effects in lipopolysaccharide-stimulated RAW264.7 macrophages

Cytokine. 2017 Mar:91:57-64. doi: 10.1016/j.cyto.2016.12.006. Epub 2016 Dec 21.

Abstract

Pseudolysimachion rotundum var. subintegrum is utilized as a traditional herbal remedy to treat cough, bronchitis, and asthma in Korea, Russia, China, and Europe. Here, we show that 3-methoxy-catalposide, a novel iridoide glycoside isolated from P. rotundum var. subintegrum has the anti-inflammatory activity in lipopolysaccharide (LPS)-stimulated macrophages. The chemical structure of 3-methoxy-catalposide was determined by NMR, optical rotation and HRESIMS. In in vitro experiment, RAW264.7 cells were treated with 3-methoxy-catalposide for 2h before exposure to LPS for different times. Inflammatory gene and protein expressions were assayed using RT-PCR and ELISA. Activities of signal proteins were examined using western analysis. Our results demonstrated that 3-methoxy-catalposide significantly inhibits the expression of cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) in RAW264.7 cells stimulated by LPS, thereby suppressing the release of prostaglandin E2 (PGE2) and nitric oxide (NO). Moreover, 3-methoxy-catalposide markedly reduced the LPS-induced expression of pro-inflammatory genes, such as interleukin (IL)-6, IL-1β, and TNF-α. Further, 3-methoxy-catalposide inhibited both LPS-induced activation of three MAP kinases (ERK 1/2, JNK, and p38) and the nuclear translocation of NF-κB and AP-1. These results support that 3-methoxy-catalposide may be a promising candidate for inflammation treatment.

Trial registration: ClinicalTrials.gov NCT02272634.

Keywords: 3-Methoxy-catalposide; AP-1; MAP kinase; NF-κB; NO; PGE(2).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Extracellular Signal-Regulated MAP Kinases / immunology*
  • Inflammation / chemically induced
  • Inflammation / drug therapy
  • Inflammation / immunology
  • Inflammation / pathology
  • Iridoid Glucosides / pharmacology*
  • Lipopolysaccharides / toxicity*
  • Macrophages / immunology*
  • Macrophages / pathology
  • Mice
  • Monokines / immunology*
  • NF-kappa B / immunology
  • RAW 264.7 Cells
  • Transcription Factor AP-1 / immunology

Substances

  • Iridoid Glucosides
  • Lipopolysaccharides
  • Monokines
  • NF-kappa B
  • Transcription Factor AP-1
  • Extracellular Signal-Regulated MAP Kinases

Associated data

  • ClinicalTrials.gov/NCT02272634